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De Novo Malignant Tumors in Organ Transplant Recipients 
By 1. PENN, C. C. HALGRIl\IS0N AND T. E. STARZL 
FOLLOWING THE INITIAL REPORTS of de 
novo malignancies in transplant recipients 
in 1968,1-3 an informal tumor registry for 
such cases was established in Denver.4 To 
date, accounts of malignant neoplasms in 39 
renal recipients have been compiled from 
our own program or else submitted by a 
number of other groups to this registry 
(Tables 1 and 2). One patient has devel-
oped a carcinoma of the stomach following 
heart transplantation (Table 1). 
INCIDENCE 
It is not possible to give accurate figures 
based on the world experience of approxi-
mately 4000 renal transplantations since the 
exact number of malignancies and the num-
bers of patients at risk at various postop-
erative times are not known. However, 
there are accurate figures from our own 
renal transplantation series. In this experi-
ence, there have been 11 patients who 
developed malignant tumors in 236 renal 
homograft recipients with potential follow-
ups of 18 months to almost 8 years. This 
incidence of 4.7 per cent does not reflect 
the true frequency of posttransplantation 
neoplasia since 52 patients died of a variety 
of other complications before the end of the 
fourth postoperative month. The 11 neo-
plasms developed in the remaining 184 pa-
tients for a partially corrected incidence of 
6.0 per cent. The rate of tumor develop-
ment in these young patients EP~ to 49 
years, average 27 years) compares with the 
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yearly incidence of 58 per 100,000 (0.058%) 
in the general population in a comparable 
age range. Even if the four skin tumors are 
excluded, the corrected incidence of malig-
nant disease (3.8%) in our series is still 
high. 
TYPE OF TUMOR 
Twenty-three of the 40 tumors in the 
world collections were of epithelial origin 
(Tables 1 and 2). The most common epi-
thelial tumors were carcinoma in situ of the 
cervix uteri (five cases), squamous cell 
carcinoma of the lip (five cases), squamous 
or basal cell skin carcinomas (four cases), 
and highly anaplastic carcinomas of uncer-
tain origin (two cases). In addition there 
was one example each of carcinoma of the 
colon, testis (embryonal cell), ovary (dys-
germinoma) and stomach. The origin of a 
widespread squamous cell carcinoma was 
never discovered in a final case. 
The 17 mesenchymal tumors were a much 
more homogenous group in that 15 were 
varieties of lymphoma including 12 exam-
ples of reticulum cell sarcoma and one case 
each of visceral Kaposi's sarcoma, lympho-
leukosarcoma and a lymphoma of unclassi-
fied type. The two other mesenchymal tu-
mors were gastrointestinal leiomyosarcomas. 
BEHAVIOR OF TUMORS 
The mesenchymal tumors occurred in a 
younger average-age group than the epi-
thelial lesions, 29 compared with 38 years. 
The former tumors occurred at an average 
of 26 months after transplantation com-
pared with the somewhat longer interval of 
33 months with the carcinomas. 
A number of epithelial tumors were of 
low-grade malignancy and could be cured 
with standard therapy (Table 1). Of the 23 
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Table I.-Epithelial Tumors in Organ Homograft Recipients 
Age at 
Immunosuppression 
Transplant Time of Splenec- Thymec- Imuran Predni- ALG 
Number Center Transplant Sex Donor tomy 
1 Denver 37 F Unrelated Yes 
living 
donor 
2 Minneapolis 28 F Brother No 
3 Montreal 38 F Cadaver No 
4 Los Angeles 38 F Mother No 
5 Richmond 33 F Sister No 
6 Denver 40 M Unrelated Yes 
living donor 
7 Denver 39 M Brother Yes 
8 Louisville 35 M Brother No 
9 Los Angeles 27 M Mother No 
10 Los Angeles 25 F Brother 1\0 
11 Denver 40 M Unrelated Yes 
living donor 
12 Denver 43 M Uncle Yes 
13 Denver 30 M Brother Yes 
14 Denver 34 M Sister Yes 
15 Minneapolis 27 M Brother Yes 
16 Nashville 47 M Cadaver No 
17 Denver 44 F Sister Yes 
18 San Francisco 46 M (a) Son Yes 
(b) Cadaver 
19 Minneapolis 16 F Cadaver No 
20 Ghent, Belgium 53 F Cadaver No 
21 Nashville 34 M Cadaver No 
22 Louisville 32 M Brother Yes 
23 Cape Town" 50 M Cadaver No 
" Heart transplant recipient. 
patients in this group 13 are currently alive 
including 13 of the 14 skin, lip, and uterine 
cervical carcinomas. In contrast, the epi-
thelial malignancies within the thorax and 
abdomen tended to be rapidly lethal (Table 
1) . 
Similarly, there was a dismal prognosis 
with the mesenchymal tumors inasmuch as 
only one of the 17 patients is still living 
(Table 2). All 12 of the kidney recipients 
in the subgroup of patients who developed 
reticulum cell sarcomas died within a short 
time, usually as the direct consequence of 
the tumor. Reticulum cell sarcoma most 
commonly involves the hematopoietic sys-
tem and invasion of the brain is uncom-
mon.5 Among the 12 transplant recipients 
with this diagnosis, there was invasion of 
tomy sone Type of Tumor 
Yes Yes Yes No Squamous cell carcinoma 
in situ 
No Yes Yes No Squamous cell carcinoma 
in situ 
No Yes Yes Yes Squamous cell carcinoma 
in situ 
No Yes Yes No Squamous cell carcinoma 
in situ 
No Yes Yes No Squamous cell carcinoma 
in situ 
No Yes Yes No Superficial squamous cell car-
cinoma 
Yes Yes Yes No Superficial squamous cell car-
cinoma 
No Yes Yes No Squamous cell carcinoma 
No Yes Yes No Squamous cell carcinoma 
No Yes Yes No Squamous cell carcinoma 
Yes Yes Yes No Squamous cell carcinoma 
No Yes Yes Yes Basal cell carcinoma 
Yes Yes Yes No Basal cell carcinoma 
No Yes Yes 1\0 Squamous cell carcinoma 
No Yes Yes No Undifferentiated carcinoma 
No Yes Yes No Undifferentiated carcinoma 
No Yes Yes Yes Moderately differentiated 
adenocarcinoma 
No Yes Yes No Alveolar cell carcinoma of 
lung 
No Yes Yes No Dysgemlinoma 
No Yes Yes No A:lenocarcinoma 
1\"0 Yes Yes No Squamous cell carcinoma 
No Yes Yes 1\0 Embryonal cell carcinoma 
No Yes Yes Yes Anaplastic small cell adeno-
carcinoma 
the bone marrow in two cases, the lymph 
nodes in three, the liver in four and the 
brain in six. At autopsy, the brain was the 
only site affected in four patients and in a 
fifth (case 32) cerebral involvement was 
the sole clinical feature although autopsy 
permission could not be obtained. 
Dr. Rupert Billingham of the \Vistar In-
stitute, Philadelphia, has suggested to us 
an interesting explanation for the predilec-
tion of reticulum cell sarcoma for the brain 
in immunosuppressed patients. The hypo-
thesis accepts the concept that there is a 
loss of "tumor surveillance" consequent to 
weakening of the immune system and fur-
ther holds that the brain would be espe-
cially vulnerable to tumor that is ordinarily 
checked by immune defenses since the 
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Table I.-Epithelial Tumors in Organ Homograft Recipients (Cont'd) 
Time After 
Number Transplantation Organs Involved 
1 50 months Cervix of uterus 
2 30 months Cervix of uterus 
3 6 months Cervix of uterus 
4 35 months Cervix of uterus; anterior 
wall of vagina 
5 36 months Cervix of uterus 
6 66 months Lower lip 
7 36 months Lower lip 
8 8 months Lower lip 
9 25 months Lower lip 
10 35 months Lower lip 
11 32 months Skin of ear 
12 33 months Nasolabial fold 
13 75 months Nasolabial fold 
14 74 months Left forearm, right forearm 
15 10 months Liver; brain; bone marrow 
16 19 months Lung, mediastinal lymph 
nodes; brain and liver 
17 31 months Lung 
18 9 months Lungs 
19 32 months Ovary; Peritoneum; medias-
tinal and axillary lymph 
nodes 
20 35 months Sigmoid colon 
21 62 months Metastases in lymph nodes 
of neck, later widespread 
metastases. Primary site 
of tumor unknown 
22 2 months Testis; abdominal organs; 
ureter of transplanted 
kidney; lung 
23 17 months Stomach; liver; mesentery; 
peritoneum 
brain is a privileged site for the transplan-
tation of tissues. 
ETIOLOGY OF TUMORS 
Preexisting Recipient Neoplasia 
A malignant tumor was proved to be 
present at the time of transplantation in 
only one of the 40 patients. A small low-
grade renal carcinoma of one of the native 
kidneys was found at the time of transplan-
tation in Case 31. When the recipient died 
there was a reticulum cell sarcoma of the 
brain but no trace of metastases from the 
renal carcinoma. 
Conceivably, three other patients could 
have had preexisting malignancies although 
this docs not seem likely. Patient 22 de-
veloped massive metastases of a testicular 
carcinoma less than 2 months after trans-
plantation. A small primary tumor of the 
Referring 
Outcome Pbysician 
Alive, no recurrence after hysterectomy 
Alive, no recurrence after hysterectomy R. L. Simmons 
Alive, no recurrence following cryosurgery K. Pritzker 
Alive, no recurrence after excision A. Gordon 
Cone biopsy, patient being observed at H. Lee 
regular intervals 
Alive, no recurrence following excision 
Alive, no recurrence following excision 
Alive, no recurrence following excision D. Leb 
Alive, no recurrence following excision R. Goldman 
Alive, no recurrence following excision R. Goldman 
No recurrence after excision, died 
of other causes 
Alive, no recurrence following excision 
Alive, no recurrence following excision 
Alive, no recurrence following excision 
Dead C. Hitchcock 
Dead C. Zukoski 
Dead 
Dead s. Konntz 
Dead W.Kelly 
Dead F. Derom 
Dead C. Zukoski 
Dead D.Leb 
Dead S.Bosman 
testis was then found that might have been 
present at the time of transplantation with 
widespread dissemination under the influ-
ence of immunosuppression. In Cases 24 
and 31 there were some neurologic symp-
toms prior to transplantation that were 
attributed to hypertensive encephalopathy 
or other manifestations of uremia. The Rnd-
ings receded after operation but neurologic 
abnormalities developed 5}f and 5 months 
later that were ultimately shown to be due 
to cerebral reticulum cell sarcomas. 
Preexi8ting Donor Neoplasia 
It is also most unlikely that the tumors 
were transmitted from the 44 donors who 
provided organs for the 40 recipients. In 27 
instances, kidneys were obtained from liv-
ing volunteers who have remained in good 
health for periods of as long as seven and 
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Table 2.-Mesenchymal Tumors in Organ Homograft Recipients 
Age at 
Imulunosuppression 
Number 
Transplant Time of Splenec- Thyrec- Predni- ALG 
Center Transplant Sex Donor tomy 
24 Denver 14 M Mother Yes 
25 Denver 23 M Father Yes 
26 Edinburgh, 
Scotland 26 F Mother No 
27 Cleveland 32 M Cadaver No 
28 Richmond 35 M Cadaver No 
29 Aukland, 
New Zealand 34 M (a) Cadaver No 
(b) Cadaver 
(c) Cadaver 
30 Auckland, 
New Zealand 46 F Cadaver No 
31 New York 18 M Uncle No 
32 New York 36 M Cadaver No 
33 Richmond 29 M Brother Yes 
34 Little Rock, 
Arkansas 21 M Father Yes 
:3.5 San Francisco 39 F Sister Yes 
3(; Richmond 17 M Father Yes 
37 Denver 20 F Father Yes 
38 New York 35 F Cadaver No 
39 Boston 34 M (a) Cadaver No 
(b) Half-sister 
40 Montreal 36 M Cadaver No 
one half years. The other 17 homo grafts 
were obtained from cadavers that, with one 
exception, were free of malignant disease. 
In Case 27 the donor had a medulloblas-
toma whereas the recipient subsequently 
developed a reticulum cell sarcoma at the 
gluteal site of an antilymphocyte globulin 
(ALG) injection among other locations. 
There was no morphologic relationship be-
tween the two tumors and probably no 
etiologic connection unless they were both 
caused by an oncogenic virus that was 
transmitted with the donor kidney. In Case 
32 the donor had a carcinoma of the colon 
resected 5 years previously but was appar-
ently free of tumor at the time of transplan-
tation. The recipient developed a reticulum 
cell sarcoma. 
Individual Immunosuppressive Agents 
It has been proposedl-4 that the malig-
nancies are an effect of iatrogenic immuno-
suppression with a consequent loss of the 
immunologic surveillance mechanism by 
which hlmor mutants are normally detected 
and destroyed. So far, a unique contribution 
tomy Imuran sone Type of Tumor 
No Yes Yes Yes Reticulum cell sarcoma 
Yes Yes Yes No Reticulum cell sarcoma 
No Yes Yes Yes Reticulum cell sarcoma 
No Yes Yes Yes Reticulum cell sarcoma 
No Yes Yes No Reticuhlll1 cell sarcoma 
No Yes Yes No Reticulum cell sarcoma 
No Yes Yes No Reticulum cell sarcoma 
No Yes Yes No Reticulum cell sarcoma 
No Yes Yes No Reticulum cell sarcoma 
No Yes Yes No Reticulum cell sarcoma 
No Yes Yes No Reticulum cell sarcoma 
1\"0 Yes Yes No Reticulum cell sarcoma 
='Jo Yes Yes No Lympholeukosarcoma 
1\"0 Yes Yes Yes Unclassified lymphoma 
1\"0 Yes Yes No Visceral Kaposfs sarcoma 
No Yes Yes No Leiomyosarcoma 
No Yes Yes No Leiomyosarcoma 
of anyone of the individual immunosup-
pressive measures has not been evident. All 
of the patients (Table 1 and 2) received 
azathioprine and prednisone, 18 underwent 
splenectomy, and five had thymectomy. 
Eight received antilymphocyte serum 
( ALS) or globulin (ALG) but in one of 
these patients (Case 26) there was radio-
logic evidence of an intrathoracic reticulum 
cell sarcoma before ALS treatment was be-
gun. Before the onset of the diagnosed 
tumor growth, many of the patients had had 
difficulties with homograft rejection and in 
an effort to control this process had re-
ceived increased doses of immunosuppres-
sive agents, especially steroids. 
Acceptance of the surveillance hypothesis 
as the indirect explanation for postransplan-
tation neoplasia does not exclude a variety 
of specific etiologic factors that could di-
rectly cause malignant transformation of 
cells. These could include a toxic effect of 
the actual immunosuppressive agents, car-
cinogens (such as tobacco, ultraviolet light 
or irradiation) in the environment or onco-
genic viruses. Concerning the last possi-
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Table 2.-Mesenehymal Tumors in Organ Homograft Recipients (Cont'd) 
Time After 
Number Transplantation Organs Involved Outcome 
Referring 
Physician 
24 5% months Brain Dead 
25 30 months Thyroid; liver; lung; stomach; prostate; pituitary; Dead 
skin; psoas muscle 
26 25 months Lymph nodes; pleura; spleen; liver; ovary; adrenal; Dead M. Woodruff 
bone marrow; and transplanted kidney 
27 22 months Buttock; lungs; aortic lymph nodes Dead S. D. Deodhnr 
J. Pierce 28 31 months Lung Dead 
29 7 Inonths Tongue, esophagus; liver Dead P. Donk 
30 9 months Brain Dead P. Doak 
31 9 months Brain Dead R. Porro 
32 10 months Brain Dead F. Veith 
33 67 months Lymph nodes; liver; vertebrae Dead H. Lee 
34 24 months Brain Dead C. Araoz 
3.5 14 months Brain; lungs Dead F. O. Belzer 
36 75 months Lymph nodes; liver; pancreas; bone marrow; 
meninges; bladder; testes; transplanted kidney, 
accessory spleen, sciatic nerve Dead H. '.1. Lee 
37 7 lllonths Brain Alive, following 
radiotherapy 
38 
39 
10 months 
47 months 
Lungs; esophagus; stomach; urinary bladder; 
mediastinal and abdominal lymph nodes 
Stomach, abdominal lymph nodes; peritoneum; 
bowel; liver; lungs; pleura and ribs 
Dead 
Dead 
Dead 
J. H. Siegel 
R. E. Wilson 
L. D. Maclean 40 51 months Small bowel; liver; pancreas 
bility, it is of interest that infections by the 
herpes family have been very common in 
transplantation recipients. Two human 
strains of this virus, the Epstein-Barr and 
herpes hominis II, have been found to be 
commonly associated with although not 
necessarily responsible for Burkitt's lymph-
oma and uterine cervical carcinoma re-
spectively. 
TREATMENT OF TUMORS 
The epithelial malignancies of the skin, 
lip and uterine cervix were successfully 
treated by standard surgical techniques 
without risking the homo grafts by arbitrary 
reductions in immunosuppression. 
The "deep" malignancies could not be 
effectively treated with this approach and 
led or contributed to death in eight of nine 
epithelial and 16 of 17 mesenchymal tu-
mors. The exceptional patient in the epi-
thelial group had an ovarian dysgerminoma 
with abdominal and intrathoracic spread. 
The primary tumor and metastases were 
treated with irradiation. She discontinued 
at least the steroid part of her immuno-
suppressive regimen and died 16 months 
after the appearance of the neoplasm and 
50 months after transplantation. At autopsy, 
residual tumor was not found. The word 
"cure" used in the title of the article re-
porting this case6 would be questionable 
with such a short followup, even in a non-
immunosuppressed patient. 
One patient is still alive among those 
with mesenchymal malignancies. She had 
a lymphoma of the basal diencephalon that 
was treated with local irradiation. In addi-
tion, her immunosuppression was drastically 
reduced despite which rejection of the renal 
homograft did not occur.2 She is in excellent 
health 3 years after transplantation and O~ 
years after the diagnosis of the tumor. 
CONCLUSIONS 
A significant incidence of de novo malig-
nancy is part of the price for successful 
organ transplantation. In our institution 11 
malignant neoplasms have been seen in 
renal recipients followed for lJ2 to 8 
years for an incidence greater than 5 
per cent. Twcnty-nine other examples of 
this complication have been collected from 
other institutions including a gastric carci-
noma in a heart recipient. Twenty-three of 
the tumors were of epithelial origin and the 
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other 17 were of mesenchymal derivation. 
"Superficial" carcinomas of the skin, lip and 
cervix were treated with uniform success 
by conventional means. "Deep" carcinomas 
in the body cavities as well as mesenchymal 
tumors led or contributed to early death in 
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almost all cases. In view of the virtually 
hopeless prognosis, drastic reductions or 
even discontinuance of immunosuppression 
could be considered in the latter kinds of 
patients. 
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